|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CYP4V2 |
Gene summary for CYP4V2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CYP4V2 | Gene ID | 285440 |
| Gene name | cytochrome P450 family 4 subfamily V member 2 | |
| Gene Alias | BCD | |
| Cytomap | 4q35.1-q35.2 | |
| Gene Type | protein-coding | GO ID | GO:0001523 | UniProtAcc | Q6ZWL3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 285440 | CYP4V2 | S43 | Human | Liver | Cirrhotic | 1.22e-03 | 1.07e-01 | -0.0187 |
| 285440 | CYP4V2 | HCC1_Meng | Human | Liver | HCC | 5.60e-18 | -8.18e-02 | 0.0246 |
| 285440 | CYP4V2 | HCC2_Meng | Human | Liver | HCC | 3.57e-15 | 5.44e-02 | 0.0107 |
| 285440 | CYP4V2 | HCC1 | Human | Liver | HCC | 1.68e-05 | 3.11e+00 | 0.5336 |
| 285440 | CYP4V2 | S027 | Human | Liver | HCC | 1.40e-02 | 5.22e-01 | 0.2446 |
| 285440 | CYP4V2 | S028 | Human | Liver | HCC | 3.36e-17 | 6.98e-01 | 0.2503 |
| 285440 | CYP4V2 | S029 | Human | Liver | HCC | 2.80e-12 | 7.03e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000820211 | Liver | Cirrhotic | steroid metabolic process | 143/4634 | 319/18723 | 2.79e-15 | 3.18e-13 | 143 |
| GO:000663112 | Liver | Cirrhotic | fatty acid metabolic process | 165/4634 | 390/18723 | 1.29e-14 | 1.26e-12 | 165 |
| GO:00161251 | Liver | Cirrhotic | sterol metabolic process | 75/4634 | 152/18723 | 4.54e-11 | 2.61e-09 | 75 |
| GO:001939512 | Liver | Cirrhotic | fatty acid oxidation | 53/4634 | 103/18723 | 4.73e-09 | 1.88e-07 | 53 |
| GO:003444011 | Liver | Cirrhotic | lipid oxidation | 53/4634 | 108/18723 | 3.85e-08 | 1.27e-06 | 53 |
| GO:00067202 | Liver | Cirrhotic | isoprenoid metabolic process | 46/4634 | 116/18723 | 2.71e-04 | 2.41e-03 | 46 |
| GO:003025811 | Liver | Cirrhotic | lipid modification | 75/4634 | 212/18723 | 3.33e-04 | 2.87e-03 | 75 |
| GO:00067212 | Liver | Cirrhotic | terpenoid metabolic process | 38/4634 | 97/18723 | 1.16e-03 | 7.89e-03 | 38 |
| GO:000663122 | Liver | HCC | fatty acid metabolic process | 238/7958 | 390/18723 | 8.24e-14 | 4.84e-12 | 238 |
| GO:00082022 | Liver | HCC | steroid metabolic process | 188/7958 | 319/18723 | 1.96e-09 | 5.63e-08 | 188 |
| GO:00161252 | Liver | HCC | sterol metabolic process | 101/7958 | 152/18723 | 1.99e-09 | 5.63e-08 | 101 |
| GO:001939522 | Liver | HCC | fatty acid oxidation | 72/7958 | 103/18723 | 1.63e-08 | 3.92e-07 | 72 |
| GO:003444021 | Liver | HCC | lipid oxidation | 73/7958 | 108/18723 | 1.17e-07 | 2.25e-06 | 73 |
| GO:003025821 | Liver | HCC | lipid modification | 123/7958 | 212/18723 | 3.50e-06 | 4.58e-05 | 123 |
| GO:000672011 | Liver | HCC | isoprenoid metabolic process | 65/7958 | 116/18723 | 2.23e-03 | 1.11e-02 | 65 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CYP4V2 | SNV | Missense_Mutation | rs780515755 | c.1246N>A | p.Gly416Ser | p.G416S | Q6ZWL3 | protein_coding | deleterious(0) | probably_damaging(0.926) | TCGA-A7-A26I-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
| CYP4V2 | SNV | Missense_Mutation | rs777774802 | c.1327C>T | p.Arg443Trp | p.R443W | Q6ZWL3 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-B6-A1KN-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| CYP4V2 | SNV | Missense_Mutation | novel | c.1539N>G | p.Ile513Met | p.I513M | Q6ZWL3 | protein_coding | deleterious(0.03) | possibly_damaging(0.516) | TCGA-VS-A9UH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CYP4V2 | SNV | Missense_Mutation | novel | c.286C>T | p.Pro96Ser | p.P96S | Q6ZWL3 | protein_coding | tolerated(0.07) | benign(0.196) | TCGA-VS-A9V5-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
| CYP4V2 | insertion | In_Frame_Ins | novel | c.1557_1558insTCCTGTCAT | p.Arg519_Arg520insSerCysHis | p.R519_R520insSCH | Q6ZWL3 | protein_coding | TCGA-DS-A1OD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | ||
| CYP4V2 | SNV | Missense_Mutation | rs140450256 | c.1573N>T | p.Arg525Cys | p.R525C | Q6ZWL3 | protein_coding | benign(0.145) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CYP4V2 | SNV | Missense_Mutation | rs775079710 | c.1574N>A | p.Arg525His | p.R525H | Q6ZWL3 | protein_coding | benign(0) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| CYP4V2 | SNV | Missense_Mutation | rs142136741 | c.832N>A | p.Ala278Thr | p.A278T | Q6ZWL3 | protein_coding | tolerated(0.57) | benign(0.009) | TCGA-CM-6171-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CYP4V2 | SNV | Missense_Mutation | rs770074074 | c.981N>C | p.Met327Ile | p.M327I | Q6ZWL3 | protein_coding | deleterious(0) | possibly_damaging(0.893) | TCGA-G4-6588-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CYP4V2 | SNV | Missense_Mutation | rs763083895 | c.662N>A | p.Arg221His | p.R221H | Q6ZWL3 | protein_coding | tolerated(0.08) | benign(0.031) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |